Standard BioTools Valuation
Is LAB undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for LAB?
Other financial metrics that can be useful for relative valuation.
|What is LAB's n/a Ratio?|
Price to Sales Ratio vs Peers
How does LAB's PS Ratio compare to its peers?
|Company||PS||Estimated Growth||Market Cap|
HBIO Harvard Bioscience
RPID Rapid Micro Biosystems
LAB Standard BioTools
Price-To-Sales vs Peers: LAB is good value based on its Price-To-Sales Ratio (1x) compared to the peer average (2.4x).
Price to Earnings Ratio vs Industry
How does LAB's PE Ratio compare vs other companies in the US Life Sciences Industry?
Price to Sales Ratio vs Fair Ratio
What is LAB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||1x|
|Fair PS Ratio||n/a|
Price-To-Sales vs Fair Ratio: Insufficient data to calculate LAB's Price-To-Sales Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of LAB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate LAB's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate LAB's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
- Examine Standard BioTools's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Potentially undervalued companies in the Pharmaceuticals & Biotech industry.